As one of only four individuals awarded in 2020, Dr. Samulski is featured alongside this year’s class of 11 winners.
Category: News
AskBio Named to Inc. 5000 List of Fastest-Growing Private Companies
AskBio ranked No. 652 by Inc. magazine on its annual Inc. 5000 list of the fastest-growing privately held companies.
AskBio Appoints Michael Kranda as SVP Therapeutic Practice Leader for Its Growing CNS Portfolio
Kranda comes to AskBio from the Allen Institute, where, since 2016, he served as senior director of business development.
AskBio CSO Jude Samulski Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine
Dr. Samulski is recognized in the Entrepreneurs category as a transformative leader in genetic medicine.
Libbie Mansell Joins AskBio as SVP Regulatory Affairs
Dr. Mansell’s 30-year career has spanned development of small molecules and biologics, resulting in nine successful approvals.
AAV Gene Therapy Pioneer Jude Samulski Develops Proprietary Regulated Gene Editing System
Technology brings together benefits of AAV and CRISPR while minimizing negative effects that occur during gene editing.
AskBio Appoints Tim Trost as Chief Financial Officer
Trost is a highly accomplished CFO with more than 25 years of experience building, managing and financing emerging life sciences companies.
AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases
Acquisition adds Huntington’s disease gene therapy candidate to AskBio’s clinical program and provides access to pipeline for additional indications.
Don Haut, PhD, Joins AskBio as Chief Business Officer
Dr. Haut brings more than two decades of healthcare experience to AskBio and will lead its business development strategy and execution.
AskBio Enters Research Collaboration and Licensing Agreement with University of North Carolina (UNC) for Angelman Syndrome
Collaboration builds upon preclinical research that demonstrates potential for gene therapy to correct UBE3A gene deficiency.
